Skip to nav Skip to content

Clinical Trial Search

293 Clinical Trials Found

Clinical Trial 23229

An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants with HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
Disease Site: Cervix, Head & Neck, Lip, Oral Cavity and Pharynx, Squamous Cell Carcinoma (SCC)
PI: Rabinowits, Guilherme

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 21131

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Disease Site: Larynx, Lip, Oral Cavity and Pharynx, Head & Neck, Mouth, lip, nasal cavity
PI: Kirtane, Kedar

Clinical Trial 21378

Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer
Disease Site: Breast
PI: Han, Heather

Clinical Trial 20530

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations
Disease Site: Lung
PI: Saltos, Andreas

Clinical Trial 21450

A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
Disease Site: Acute Leukemia (ALL, AML), Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 20752

A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia
PI: Chan, Onyee

Clinical Trial 21383

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
Disease Site: Other Digestive Organ, Other Endocrine System
PI: Strosberg, Jonathan

Clinical Trial 23486

Disease Site: Brain and Nervous System
PI: Oliver, Daniel

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Disease Site: Bones and Joints, Rhabdomyosarcoma
PI: Metts, Jonathan

Clinical Trial 21122

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 20110

GBM Agile: Global Adaptive Trial Master Protocol
Disease Site: Brain and Nervous System
PI: Grogan, Patrick